RU2010129298A - METHOD FOR IMPROVING PHARMACOLOGICAL ACTIVITY OF AN ACTING SUBSTANCE OF MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION - Google Patents
METHOD FOR IMPROVING PHARMACOLOGICAL ACTIVITY OF AN ACTING SUBSTANCE OF MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION Download PDFInfo
- Publication number
- RU2010129298A RU2010129298A RU2010129298/15A RU2010129298A RU2010129298A RU 2010129298 A RU2010129298 A RU 2010129298A RU 2010129298/15 A RU2010129298/15 A RU 2010129298/15A RU 2010129298 A RU2010129298 A RU 2010129298A RU 2010129298 A RU2010129298 A RU 2010129298A
- Authority
- RU
- Russia
- Prior art keywords
- activated
- disease
- potentiated form
- active substance
- super
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 12
- 230000000144 pharmacologic effect Effects 0.000 title claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title claims 5
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims abstract 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 14
- 239000013543 active substance Substances 0.000 claims abstract 12
- 239000003814 drug Substances 0.000 claims abstract 9
- 229940079593 drug Drugs 0.000 claims abstract 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract 8
- 230000002708 enhancing effect Effects 0.000 claims abstract 8
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims abstract 7
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims abstract 7
- 230000003511 endothelial effect Effects 0.000 claims abstract 7
- 239000000427 antigen Substances 0.000 claims abstract 5
- 102000036639 antigens Human genes 0.000 claims abstract 5
- 108091007433 antigens Proteins 0.000 claims abstract 5
- 230000008506 pathogenesis Effects 0.000 claims abstract 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000002360 preparation method Methods 0.000 claims abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract 2
- 102000004877 Insulin Human genes 0.000 claims abstract 2
- 108090001061 Insulin Proteins 0.000 claims abstract 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims abstract 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims abstract 2
- 208000006011 Stroke Diseases 0.000 claims abstract 2
- 230000001154 acute effect Effects 0.000 claims abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract 2
- 210000004556 brain Anatomy 0.000 claims abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract 2
- 230000001684 chronic effect Effects 0.000 claims abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 2
- 239000002552 dosage form Substances 0.000 claims abstract 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims abstract 2
- 229940125396 insulin Drugs 0.000 claims abstract 2
- 210000002307 prostate Anatomy 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 239000000654 additive Substances 0.000 claims 2
- 210000004900 c-terminal fragment Anatomy 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ повышения фармакологической активности действующего вещества лекарственного средства на основе активированной-потенцированной формы сверхразбавленных антител к антигену, участвующему в патогенезе заболевания, для которого применяют указанное лекарственное средство, путем введения - совмещения с усиливающим агентом, отличающийся тем, что усиливающим агентом является активированная-потенцированная форма сверхразбавленных антител к эндотелиальной NO-синтазе. ! 2. Способ по п.1, отличающийся тем, что лекарственное средство с действующим веществом и усиливающий агент на основе активированной-потенцированной формы сверхразбавленных антител к эндотелиальной NO-синтазе используют одновременно и сочетано в виде единого препарата - одной лекарственной формы или совместно в виде различных препаратов. ! 3. Способ по п.1, отличающийся тем, что указанным заболеванием являются заболевания предстательной железы, а действующее вещество представляет собой активированную-потенцированную форму сверхразбавленных антител к простатоспецифическому антигену. ! 4. Способ по п.1, отличающийся тем, что указанным заболеванием являются острые и хронические нарушения мозгового кровообращения, или синдром дефицита внимания, или болезнь Альцгеймера, а действующее вещество представляет собой активированную-потенцированную форму сверхразбавленных антител к мозгоспецифическому белку S-100. ! 5. Способ по п.1, отличающийся тем, что указанным заболеванием является сахарный диабет у инсулино-резистентных больных, а действующее вещество представляет собой активированную-потенцированную форму сверхразбавленных антител к С-� 1. A method of increasing the pharmacological activity of the active substance of a drug on the basis of an activated-potentiated form of super-diluted antibodies to an antigen involved in the pathogenesis of a disease for which the drug is used, by administering - combining with an enhancing agent, characterized in that the enhancing agent is an activated potentiated form of over-diluted antibodies to endothelial NO synthase. ! 2. The method according to claim 1, characterized in that the drug with the active substance and the enhancing agent based on the activated-potentiated form of ultra-diluted antibodies to endothelial NO synthase are used simultaneously and combined in the form of a single preparation - one dosage form or together in the form of various preparations. ! 3. The method according to claim 1, characterized in that the indicated disease is a disease of the prostate gland, and the active substance is an activated-potentiated form of super-diluted antibodies to a prostate-specific antigen. ! 4. The method according to claim 1, characterized in that the disease is acute and chronic cerebrovascular accident, or attention deficit disorder, or Alzheimer's disease, and the active substance is an activated-potentiated form of super-diluted antibodies to brain-specific protein S-100. ! 5. The method according to claim 1, characterized in that said disease is diabetes mellitus in insulin-resistant patients, and the active substance is an activated-potentiated form of super-diluted antibodies to C-�
Claims (10)
Priority Applications (34)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010129298/15A RU2526153C2 (en) | 2010-07-15 | 2010-07-15 | Method for increase of pharmacological activity of active agent of drug preparation and pharmaceutical composition |
| KR1020137003861A KR20140014059A (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| CN2011800443324A CN103108657A (en) | 2010-07-15 | 2011-07-15 | Method of increasing the effect of an antibody in a potentiated form |
| NZ606767A NZ606767A (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| MX2013000543A MX2013000543A (en) | 2010-07-15 | 2011-07-15 | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract. |
| EA201300126A EA030566B1 (en) | 2010-07-15 | 2011-07-15 | Method of increasing therapeutic effectiveness of an activated-potentiated form of an antibody to an endogenous biological molecule and pharmaceutical composition |
| FR1156482A FR2962656A1 (en) | 2010-07-15 | 2011-07-15 | METHOD FOR INCREASING THE EFFECT OF AN ACTIVATED-POTENTIALIZED FORM OF ANTIBODY |
| GB1302649.7A GB2495884B (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| ES201390006A ES2440393R1 (en) | 2010-07-15 | 2011-07-15 | A METHOD FOR INCREASING THE EFFECT OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY |
| SE1350184A SE1350184A1 (en) | 2010-07-15 | 2011-07-15 | PROCEDURE TO INCREASE THE EFFECT OF AN ACTIVATED, POTENTIZED FORM OF AN ANTIBODY |
| EEP201300006A EE201300006A (en) | 2010-07-15 | 2011-07-15 | A pharmaceutical composition for enhancing the effect of an activated and potentiated form of an antibody |
| SG10201505561TA SG10201505561TA (en) | 2010-07-15 | 2011-07-15 | A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody |
| IT000639A ITTO20110639A1 (en) | 2010-07-15 | 2011-07-15 | METHOD TO INCREASE THE EFFECT OF AN ACTIVE-ENHANCED SHAPE OF AN ANTI-BODY |
| PCT/IB2011/002350 WO2012007845A2 (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| FI20135143A FI20135143A7 (en) | 2010-05-20 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| DE112011102358T DE112011102358T5 (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| EP11775838.3A EP2593140A2 (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| SG2013002324A SG187038A1 (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| PE2013000076A PE20130398A1 (en) | 2010-07-15 | 2011-07-15 | A METHOD TO INCREASE THE EFFECT OF AN ACTIVE ENHANCED FORM OF AN ANTIBODY |
| PH1/2013/500107A PH12013500107A1 (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| BR112013000840A BR112013000840A2 (en) | 2010-07-15 | 2011-07-15 | method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase. |
| US13/135,901 US9308275B2 (en) | 2010-07-15 | 2011-07-15 | Method of increasing the effect of an activated-potentiated form of an antibody |
| JP2013519175A JP2013538186A (en) | 2010-07-15 | 2011-07-15 | Method for increasing the effect of activation-enhancing antibodies |
| CA2804966A CA2804966A1 (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| CZ20130105A CZ2013105A3 (en) | 2010-07-15 | 2011-07-15 | Method of increasing effect of antibody activated potentiated form |
| AU2011278038A AU2011278038B2 (en) | 2010-07-15 | 2011-07-15 | A method of increasing the effect of an activated-potentiated form of an antibody |
| ARP110102578A AR082247A1 (en) | 2010-07-15 | 2011-07-18 | A METHOD FOR INCREASING THE EFFECTS OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY |
| CL2013000099A CL2013000099A1 (en) | 2010-07-15 | 2013-01-10 | A method of increasing the effect of an potentiated active form of an antibody to an endogenous biological molecule, comprising the combination of the endogenous biological molecule with an enhanced active form of an endoltelial non-synthase antibody; composition that understands it. |
| NO20130222A NO20130222A1 (en) | 2010-07-15 | 2013-02-08 | Process for increasing the effect of an activated-potentiated form of an antibody |
| DKPA201370079A DK201370079A (en) | 2010-07-15 | 2013-02-14 | A method of increasing the effect of an activated-potentiated form of an antibody |
| LT2013016A LT5988B (en) | 2010-07-15 | 2013-02-14 | A method of increasing the effect of an activated-potentiated form of an antibody |
| US15/060,157 US20160244531A1 (en) | 2010-07-15 | 2016-03-03 | Method of increasing the effect of an activated-potentiated form of an antibody |
| US15/060,202 US20160251448A1 (en) | 2010-07-15 | 2016-03-03 | Method of increasing the effect of an activated-potentiated form of an antibody |
| JP2016135750A JP2016216483A (en) | 2010-07-15 | 2016-07-08 | Method for increasing the effect of activation-enhancing antibodies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010129298/15A RU2526153C2 (en) | 2010-07-15 | 2010-07-15 | Method for increase of pharmacological activity of active agent of drug preparation and pharmaceutical composition |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014126438A Division RU2651005C2 (en) | 2014-06-30 | 2014-06-30 | Method of increasing the pharmacological activity of the activated-potentiated form of antibodies to the prostate-specific antigen and the pharmaceutical composition |
| RU2014126438A Substitution RU2651005C2 (en) | 2014-06-30 | 2014-06-30 | Method of increasing the pharmacological activity of the activated-potentiated form of antibodies to the prostate-specific antigen and the pharmaceutical composition |
| RU2014126440/15A Division RU2572706C1 (en) | 2014-06-30 | 2014-06-30 | Method for increasing pharmacological activity of active substance of medicinal product and pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010129298A true RU2010129298A (en) | 2012-01-20 |
| RU2526153C2 RU2526153C2 (en) | 2014-08-20 |
Family
ID=45785353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010129298/15A RU2526153C2 (en) | 2010-05-20 | 2010-07-15 | Method for increase of pharmacological activity of active agent of drug preparation and pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2526153C2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2651005C2 (en) * | 2014-06-30 | 2018-04-18 | Олег Ильич Эпштейн | Method of increasing the pharmacological activity of the activated-potentiated form of antibodies to the prostate-specific antigen and the pharmaceutical composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| RU2253477C1 (en) * | 2003-10-01 | 2005-06-10 | Эпштейн Олег Ильич | Method of enhancing potentiation of specific effects of drug or substance |
-
2010
- 2010-07-15 RU RU2010129298/15A patent/RU2526153C2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2526153C2 (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jackson et al. | Within the brain: the renin angiotensin system | |
| JP2013538195A5 (en) | ||
| EA200800033A1 (en) | COMPOSITION (OPTIONS), METHOD FOR ITS PREPARATION, TANK CONTAINING CONTAINING THE SPECIFIED COMPOSITION, AND METHOD FOR TREATING VIRAL DISEASES WITH ITS USE | |
| JP2013533268A5 (en) | ||
| RU2010133045A (en) | MEDICINAL PRODUCT AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS | |
| EA201590797A1 (en) | PREPARATIONS WITH THE MODIFIED PROBE RELEASE | |
| AR082313A1 (en) | PHARMACEUTICAL COMBINATION COMPOSITION TO TREAT DISEASES OR CONDITIONS ASSOCIATED WITH A RESPIRATORY DISEASE OR CONDITION | |
| RU2016144190A (en) | STABLE PROTEIN PRODUCTS CONTAINING MOLAR EXCESS OF SORBITOL | |
| RU2010129298A (en) | METHOD FOR IMPROVING PHARMACOLOGICAL ACTIVITY OF AN ACTING SUBSTANCE OF MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION | |
| RU2010133053A (en) | INTEGRATED MEDICINE FOR TREATMENT OF VIRAL DISEASES AND METHOD OF TREATMENT OF VIRAL DISEASES | |
| RU2011127059A (en) | NEUROTROPIC MEDICINE AND METHOD OF TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS | |
| RU2011127052A (en) | METHOD FOR TREATING THE HEAD-VARIABLE OF VARIOUS GENESIS, KINETOSIS AND VEGETOVASCULAR DYSTONIA (OPTIONS) AND MEDICINAL PRODUCT | |
| RU2011127058A (en) | MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | |
| JP2020040998A5 (en) | ||
| RU2011127051A (en) | MEDICINAL PRODUCT FOR REDUCING RESISTANCE TO INSULIN AND FOR TREATING SUGAR DIABETES, METHOD FOR REDUCING RESISTANCE TO INSULIN, METHOD FOR TREATING SUGAR DIABETES AND METHOD FOR TREATING ISOMEPHELIUM IN SUCHEMIUM | |
| Singer et al. | SSR504734 enhances basal expression of prepulse inhibition but exacerbates the disruption of prepulse inhibition by apomorphine | |
| RU2010130358A (en) | MEDICINE FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME AND METHOD FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME | |
| RU2011127055A (en) | MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT | |
| RU2013154072A (en) | MEDICINE FOR TREATMENT OF KINETOSIS AND METHOD OF TREATMENT OF KINETOSIS | |
| RU2010130353A (en) | MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | |
| RU2014126438A (en) | A method of increasing the pharmacological activity of an activated-potentiated form of antibodies to a prostate-specific antigen and a pharmaceutical composition | |
| RU2010133051A (en) | COMPREHENSIVE MEDICINE FOR TREATMENT OF INFLUENZA TREATMENT OF VARIOUS TYPES | |
| RU2010133047A (en) | INTEGRATED MEDICINE AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS | |
| RU2010133043A (en) | INTEGRATED MEDICINE AND METHOD FOR PREVENTION AND TREATMENT OF INFECTIOUS VIRAL DISEASES | |
| RU2010130355A (en) | MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20120521 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20130305 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200716 |